ROIV
Roivant Sciences Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow -7.7% ·
net new positions +8.3%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | +11 | 408.23M | $14.45B | +15 | −3 |
| Q1 2026 | 122 | +5 | 384.63M | $10.65B | +13 | −9 |
| Q4 2025 | 117 | +1 | 374.22M | $8.12B | +3 | −1 |
| Q3 2025 | 19 | +1 | 262.46M | $3.97B | +1 | −1 |
| Q2 2025 | 16 | +1 | 211.12M | $2.38B | +1 | — |
| Q1 2025 | 12 | +1 | 89.39M | $901.93M | +2 | −1 |
| Q4 2024 | 11 | -2 | 96.86M | $1.15B | — | −2 |
| Q3 2024 | 12 | -1 | 85.45M | $986.08M | +1 | −2 |
| Q2 2024 | 13 | — | 92.40M | $976.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 46.01M | -3.8% | $464.28M | 1.5% | ▼ Trim | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 18.86M | -9.3% | $190.31M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 7.97M | +2.5% | $80.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 7.97M | +2.5% | $80.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Greenlight Capital (DME Capital) ✦ | 5.44M | +3.2% | $54.90M | 2.8% | ▲ Add | 4 | SEC ↗ |
| 6 | Greenlight Capital (DME Capital) ✦ | 5.44M | +3.2% | $54.90M | 2.8% | ▲ Add | 4 | SEC ↗ |
| 7 | Greenlight Capital (DME Capital) ✦ | 5.44M | +3.2% | $54.90M | 2.8% | ▲ Add | 4 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 4.58M | +3.4% | $46.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 3.82M | -33.2% | $38.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.35M | -25.1% | $13.64M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 614.32K | New | $6.20M | 0.0% | New | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 271.82K | -90.8% | $2.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 261.04K | +5.2% | $2.63M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Millennium Management ✦ | 162.75K | New | $1.64M | 0.0% | New | 1 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 39.03K | 0.0% | $393,782 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $6.20M | 0.0% |
| Millennium Management | $1.64M | 0.0% |
Exited
| Two Sigma Investments | $143,143 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 436 holders, 528.48M shares, $14.35B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 144.76K sh · $5.28M
Officer, Director · 17.52K sh · $653,459
Officer, Director · 172.90K sh · $6.43M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology